XML 56 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Feb. 29, 2024
Dec. 31, 2024
Dec. 31, 2023
Net loss   $ 80,604 $ 36,949
Cash flow used in operations   70,760 33,459
Accumulated deficit   (269,158) $ (188,554)
Cash, cash equivalents and marketable securities   $ 183,500  
Common Stock [Member]      
Issuance of common stock 19,736,842 19,736,842  
Share price per share $ 8.74    
Proceeds net of issuance costs $ 161,800    
Buccal Cells [Member] | Beginning of Study [Member]      
Percentage of increasing from mean level   15.00%  
Buccal Cells [Member] | End of Study [Member]      
Percentage of increasing from mean level   30.00%  
Skin Cells [Member] | Beginning of Study [Member]      
Percentage of increasing from mean level   16.00%  
Skin Cells [Member] | End of Study [Member]      
Percentage of increasing from mean level   72.00%